Objective: The aim of the study was to compare the results of a 2013 nationwide survey of 1001 women representative of the Swedish female population with the results of a similar survey carried out in 2017, after new guidelines for contraceptive use were published in 2014. Methods: Women between 16 and 49 years of age took part in a telephone survey; questions covered demographics, contraceptive use, knowledge of and attitudes towards contraception, importance of monthly bleeding, and experience of unintended pregnancy. We compared the responses collected in 2013 with those collected in 2017. Results: Of all women in 2017, 717/1008 (71.1%) were currently using contraception; 291/1008 (28.9%) women were not. Long-acting reversible contraception (LARC) was used by 311/1008 (30.9%) women, which was a significant increase from 2013 (243/1001, 24.3%; p ¼ .001). The unmet need for contraception in Sweden in 2017 was estimated to be 15.2%. A total of 783 (77.7%) women had never experienced an unintended pregnancy. A significantly higher proportion of unintended pregnancies reported in 2017 were terminated compared with 2013. Conclusion: Sweden has a large unmet need for contraception. In 2017, LARC use had increased compared with 2013. A large proportion of women had experienced an unintended pregnancy. Increasing overall contraceptive use is important to reduce the rates of unintended and unwanted pregnancies.

BackgroundAutologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality.MethodsAll 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, including CD34+ cell amounts, medications, infectious and other complications, intensive care, longitudinal laboratory values, and secondary myeloid neoplasia.ResultsThe 100-day non-relapse and overall mortalities were 5.6% and 7.2%. Stem-cell harvests < 5 million CD34+ cells/kg correlated with inferior 100-day and long-term survival. Prior to conditioning (93% BEAM), elevated (both 3–9 and ≥ 10 mg/L) C-reactive protein (CRP) and creatinine, and low albumin (but not higher age) predicted inferior higher 100-day survival. Intravenous antibiotics were given to 97% (22% positive blood cultures) and parenteral nutrition to 89%. After 1 year, 86% had normalized hemoglobin. The 5-year risk for secondary myeloid neoplasia was 4.1%, associated with smaller harvests.ConclusionsBefore starting conditioning, patients should have preferably harvested ≥ 5 million CD34+ cells/kg and normal CRP, albumin, and creatinine. It appears safe to transplant patients ≥ 66 years.Electronic supplementary materialThe online version of this article (10.1186/s40164-019-0131-3) contains supplementary material, which is available to authorized users.

No abstract